ELITEK
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $13,651 | 20 | 19 |
| 2023 | $91,798 | 985 | 882 |
| 2022 | $265,358 | 2,561 | 1,726 |
| 2021 | $208,823 | 1,958 | 1,257 |
| 2020 | $167,942 | 1,534 | 1,013 |
| 2019 | $774,026 | 4,047 | 2,026 |
| 2018 | $209,367 | 1,462 | 854 |
| 2017 | $238,116 | 1,216 | 692 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 1,333 | 51.9% |
| Consulting Fee | $295,044 | 86 | 15.0% |
| Food and Beverage | $265,404 | 11,212 | 13.5% |
| Travel and Lodging | $168,374 | 395 | 8.6% |
| Space rental or facility fees (teaching hospital only) | $141,000 | 80 | 7.2% |
| Education | $59,392 | 670 | 3.0% |
| Unspecified | $18,324 | 7 | 0.9% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prevention and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based therapy | GENZYME CORPORATION | $12,137 | 0 |
| Health Economic Evaluation of Rasburicase (Faturec) for the treatment and prophylaxis of hyperuricemia | SANOFI-AVENTIS U.S. LLC | $5,097 | 2 |
| Patterns of use of rasburicase in community oncology programs and impact on tumor lysis syndrome outcomes | SANOFI-AVENTIS U.S. LLC | $1,090 | 2 |
Top Doctors Receiving Payments for ELITEK
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Worcester, MA | $216,135 | 146 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $208,830 | 117 |
| Unknown | — | Orlando, FL | $181,046 | 120 |
| , MD | Nephrology | Saint Louis, MO | $83,956 | 71 |
| , MD | Internal Medicine | Tampa, FL | $62,450 | 32 |
| Michael Bishop | Hematology & Oncology | Burr Ridge, IL | $43,647 | 19 |
| , MD | Pediatric Hematology-Oncology | Valhalla, NY | $40,083 | 21 |
| , M.D | Hematology | Hawthorne, NY | $39,710 | 23 |
| , M.D | Medical Oncology | Durham, NC | $39,271 | 21 |
| , MD | Internal Medicine | Denver, CO | $37,125 | 51 |
| , M.D | Internal Medicine | Greenbelt, MD | $32,041 | 43 |
| , MBBS | Internal Medicine | Charlotte, NC | $30,695 | 20 |
| , MD | Hematology & Oncology | Indianapolis, IN | $27,954 | 28 |
| , MD | Internal Medicine | La Jolla, CA | $25,789 | 17 |
| , APRN | Nurse Practitioner | Wethersfield, CT | $24,479 | 43 |
| , MD | Hematology & Oncology | Gilbert, AZ | $23,948 | 34 |
| , M.D | Hematology & Oncology | Danville, KY | $22,649 | 31 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $22,325 | 32 |
| , M.D | Hematology & Oncology | Shelbyville, TN | $22,109 | 36 |
| , MD | Hematology & Oncology | La Mesa, CA | $19,768 | 16 |
| , MD | Internal Medicine | Charlotte, NC | $18,896 | 18 |
| , MD | Internal Medicine | New York, NY | $17,947 | 43 |
| , MD | Hematology & Oncology | Oklahoma City, OK | $15,780 | 18 |
| , MD | Hematology & Oncology | Orange, CA | $15,158 | 8 |
| , MD | Hematology & Oncology | New Orleans, LA | $15,107 | 9 |
Manufacturing Companies
- GENZYME CORPORATION $1.8M
- SANOFI-AVENTIS U.S. LLC $100,953
- BIOVERATIV THERAPEUTICS INC. $47,377
- sanofi-aventis U.S. LLC $15.92
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 5,058
- Transactions 13,783
About ELITEK
ELITEK is a drug associated with $2.0M in payments to 5,058 healthcare providers, recorded across 13,783 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $13,651 was paid across 20 transactions to 19 doctors.
The most common payment nature for ELITEK is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M, 51.9% of total).
ELITEK is associated with 3 research studies, including "Prevention and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based therapy" ($12,137).